Jay R. Luly

Jay R. Luly is a declared insider of Enanta Pharmaceuticals Inc (chief executive), with filings sourced from SEC (Form 4). Over a trading history stretching from 15 September 2021 to 12 February 2026, the count stands at 22 filings.

The open-market side counts 1 purchase for €247k alongside 4 sales for €387k. Netting one side against the other leaves €140k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 13 share grants and 4 option exercises.

Most recently, on 13 February 2026, the filings show a share grant in Enanta Pharmaceuticals Inc. The most recent open-market purchase was published on 12 February 2025, 613 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.